Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Wong NCW"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Wasiak S; Resverlogix Corp., Suite 300, 4820 Richard Road SW, Calgary, AB, T3e 6L1, Canada., Fu L; Resverlogix Corp., Suite 300, 4820 Richard Road SW, Calgary, AB, T3e 6L1, Canada., Daze E; Resverlogix Corp., Suite 300, 4820 Richard Road SW, Calgary, AB, T3e 6L1, Canada., Gilham D; Resverlogix Corp., Suite 300, 4820 Richard Road SW, Calgary, AB, T3e 6L1, Canada., Rakai BD; Resverlogix Corp., Suite 300, 4820 Richard Road SW, Calgary, AB, T3e 6L1, Canada., Stotz SC; Resverlogix Corp., Suite 300, 4820 Richard Road SW, Calgary, AB, T3e 6L1, Canada., Tsujikawa LM; Resverlogix Corp., Suite 300, 4820 Richard Road SW, Calgary, AB, T3e 6L1, Canada., Sarsons CD; Resverlogix Corp., Suite 300, 4820 Richard Road SW, Calgary, AB, T3e 6L1, Canada., Studer D; Department of Biomedical Engineering, Department of Physiology and Pharmacology, Libin Cardiovascular Institute, University of Calgary, 2500 University Dr. NW, Calgary, AB, T2N 1N4, Canada., Rinker KD; Department of Biomedical Engineering, Department of Physiology and Pharmacology, Libin Cardiovascular Institute, University of Calgary, 2500 University Dr. NW, Calgary, AB, T2N 1N4, Canada., Jahagirdar R; Resverlogix Corp., Suite 300, 4820 Richard Road SW, Calgary, AB, T3e 6L1, Canada., Wong NCW; Resverlogix Corp., Suite 300, 4820 Richard Road SW, Calgary, AB, T3e 6L1, Canada., Sweeney M; Resverlogix Corp., 535 Mission Street, 14th Floor, San Francisco, CA, 94105, USA., Johansson JO; Resverlogix Corp., 535 Mission Street, 14th Floor, San Francisco, CA, 94105, USA., Kulikowski E; Resverlogix Corp., Suite 300, 4820 Richard Road SW, Calgary, AB, T3e 6L1, Canada.
Publikováno v:
Translational neuroscience [Transl Neurosci] 2023 Dec 31; Vol. 14 (1), pp. 20220332. Date of Electronic Publication: 2023 Dec 31 (Print Publication: 2023).
Autor:
Fu L; Resverlogix Corporation, Calgary, AB, Canada., Gilham D; Resverlogix Corporation, Calgary, AB, Canada., Stotz SC; Resverlogix Corporation, Calgary, AB, Canada., Sarsons CD; Resverlogix Corporation, Calgary, AB, Canada., Rakai BD; Resverlogix Corporation, Calgary, AB, Canada., Tsujikawa LM; Resverlogix Corporation, Calgary, AB, Canada., Wasiak S; Resverlogix Corporation, Calgary, AB, Canada., Johansson JO; Resverlogix Corporation, Calgary, AB, Canada., Sweeney M; Resverlogix Corporation, Calgary, AB, Canada., Wong NCW; Resverlogix Corporation, Calgary, AB, Canada., Kulikowski E; Resverlogix Corporation, Calgary, AB, Canada. Electronic address: ewelina@resverlogix.com.
Publikováno v:
International immunopharmacology [Int Immunopharmacol] 2023 Apr; Vol. 117, pp. 109929. Date of Electronic Publication: 2023 Feb 23.
Autor:
Wasiak S; Resverlogix Corp., 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada., Tsujikawa LM; Resverlogix Corp., 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada., Daze E; Resverlogix Corp., 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada., Gilham D; Resverlogix Corp., 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada., Stotz SC; Resverlogix Corp., 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada., Rakai BD; Resverlogix Corp., 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada., Sarsons CD; Resverlogix Corp., 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada., Fu L; Resverlogix Corp., 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada., Azhar S; VA Palo Alto Health Care System, 3801 Miranda Avenue, Palo Alto, CA, 94304, USA., Jahagirdar R; Resverlogix Corp., 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada., Sweeney M; Resverlogix Inc., 535 Mission St, 14th Floor, San Francisco, CA, 94105., Johansson JO; Resverlogix Inc., 535 Mission St, 14th Floor, San Francisco, CA, 94105., Wong NCW; Resverlogix Corp., 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada., Kulikowski E; Resverlogix Corp., 300-4820 Richard Road SW, Calgary, AB, T3E 6L1, Canada. Electronic address: Ewelina@resverlogix.com.
Publikováno v:
Atherosclerosis [Atherosclerosis] 2023 Jan; Vol. 364, pp. 10-19. Date of Electronic Publication: 2022 Nov 23.
Autor:
Toth PP; CGH Medical Center Sterling, Sterling, IL, USA.; Division of Cardiology, Cicarrone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Schwartz GG; Division of Cardiology, University of Colorado School of Medicine, Aurora, CO, USA., Nicholls SJ; Monash Cardiovascular Research Centre, Monash University, Melbourne, Australia., Khan A; Resverlogix Corp., Calgary, Alberta, Canada., Szarek M; CPC Clinical Research and University of Colorado Anschutz Medical Campus, Aurora, CO, USA.; State University of New York Downstate School of Public Health, Brooklyn, NY, USA., Ginsberg HN; Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA., Johansson JO; Resverlogix Corp., Calgary, Alberta, Canada., Kalantar-Zadeh K; Division of Nephrology and Hypertension, University of California Irvine, Irvine, CA, USA., Kulikowski E; Resverlogix Corp., Calgary, Alberta, Canada., Lebioda K; Resverlogix Corp., Calgary, Alberta, Canada., Wong NCW; Resverlogix Corp., Calgary, Alberta, Canada., Sweeney M; Resverlogix Corp., Calgary, Alberta, Canada., Ray KK; Imperial Centre for Cardiovascular Disease Prevention, Imperial College, London, UK.
Publikováno v:
American journal of preventive cardiology [Am J Prev Cardiol] 2022 Aug 08; Vol. 11, pp. 100372. Date of Electronic Publication: 2022 Aug 08 (Print Publication: 2022).
Autor:
Tsujikawa LM; Resverlogix Corporation, Suite 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada. Electronic address: laura@resverlogix.com., Kharenko OA; Resverlogix Corporation, Suite 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada. Electronic address: olesya@resverlogix.com., Stotz SC; Resverlogix Corporation, Suite 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada. Electronic address: sstotz@resverlogix.com., Rakai BD; Resverlogix Corporation, Suite 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada. Electronic address: bdrakai@gmail.com., Sarsons CD; Resverlogix Corporation, Suite 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada. Electronic address: chris@resverlogix.com., Gilham D; Resverlogix Corporation, Suite 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada. Electronic address: dean@resverlogix.com., Wasiak S; Resverlogix Corporation, Suite 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada. Electronic address: sylwia@resverlogix.com., Fu L; Resverlogix Corporation, Suite 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada. Electronic address: li@resverlogix.com., Sweeney M; Resverlogix Corporation, Suite 4010, 44 Montgomery Street, San Francisco, CA 94104, USA. Electronic address: msweeney@resverlogix.com., Johansson JO; Resverlogix Corporation, Suite 4010, 44 Montgomery Street, San Francisco, CA 94104, USA. Electronic address: jan@resverlogix.com., Wong NCW; Resverlogix Corporation, Suite 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada. Electronic address: norm@resverlogix.com., Kulikowski E; Resverlogix Corporation, Suite 300, 4820 Richard Road SW, Calgary, AB T3E 6L1, Canada. Electronic address: ewelina@resverlogix.com.
Publikováno v:
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2022 Aug; Vol. 152, pp. 113230. Date of Electronic Publication: 2022 Jun 07.
Autor:
Fu L; Resverlogix Corp, Calgary, AB, Canada., Wasiak S; Resverlogix Corp, Calgary, AB, Canada., Tsujikawa LM; Resverlogix Corp, Calgary, AB, Canada., Rakai BD; Resverlogix Corp, Calgary, AB, Canada., Stotz SC; Resverlogix Corp, Calgary, AB, Canada., Wong NCW; Resverlogix Corp, Calgary, AB, Canada., Johansson JO; Resverlogix Inc, San Francisco, California, USA., Sweeney M; Resverlogix Inc, San Francisco, California, USA., Mohan CM; Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada., Khan A; Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.; Metabolics and Genetics in Calgary (M.A.G.I.C.) Clinic Ltd., Calgary, AB, Canada., Kulikowski E; Resverlogix Corp, Calgary, AB, Canada.
Publikováno v:
Pharmacology research & perspectives [Pharmacol Res Perspect] 2022 Jun; Vol. 10 (3), pp. e00949.
Autor:
Haas MJ; Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Florida College of Medicine, Jacksonville, Florida, USA., Parekh S; Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Florida College of Medicine, Jacksonville, Florida, USA., Kalidas P; Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Florida College of Medicine, Jacksonville, Florida, USA., Richter A; Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Florida College of Medicine, Jacksonville, Florida, USA., Warda F; Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Florida College of Medicine, Jacksonville, Florida, USA., Wong NCW; Resverlogix Corp., Calgary, Alberta, Canada., Tokuda M; Department of Cell Physiology, Faculty of Medicine, Kagawa University, Kagawa, Japan., Mooradian AD; Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Florida College of Medicine, Jacksonville, Florida, USA.
Publikováno v:
Journal of food biochemistry [J Food Biochem] 2022 Feb; Vol. 46 (2), pp. e14064. Date of Electronic Publication: 2022 Jan 05.